NCT03453346 - Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis C | Biotech Hunter

Enrollment

136

Participants

Timeline

Start Date

August 5, 2016

Primary Completion Date

March 18, 2017

Study Completion Date

March 30, 2017

Conditions

Hepatitis C, ChronicHepatitis C Virus Infection, Response to Therapy of

Interventions

DRUG

Sofosbuvir

Generic sofosbuvir tablet 400 mg

DRUG

Ribavirin

Ribavirin was provided in 100-mg tablets.

Trial Locations (17)

50051

Hebei Medical University Affiliated Third Hospital, Shijiazhuang

100039

Chinese PLA 302 Hospital, Beijing

100044

Peking University People's Hospital, Beijing

100050

Capital Medical University Affiliated Beijing Youyi Hospital, Beijing

100069

Capital Medical University Affiliated Beijing You'an Hospital, Beijing

100102

Capital Medical University Affiliated Beijing Ditan Hospital, Beijing

110006

Shenyang Municipal Sixth People's Hospital, Shenyang

130021

Jilin University First Hospital, Changchun

210003

Nanjing Municipal Second Hospital, Nanjing

266011

Qingdao Municipal Hospital, Qingdao

400010

Chongqing Medical University Affiliated Second Hospital, Chongqing

400038

Chinese PLA Third Military Medical University First Affiliated Hospital, Chongqing

450003

He'nan Provincial People's Hospital, Zhengzhou

450015

He'nan Provincial Hospital of Infectious Disease (Zhengzhou Municipal Sixth People's Hospital), Zhengzhou

610072

Sichuan Provincial People's Hospital, Chengdu

710038

Chinese PLA Fourth Military Medical University Tangdu Hospital, Xi'an

710061

Xi'an Jiaotong University College of Medicine Affiliated First Hospital, Xi'an

All Listed Sponsors

collaborator

KawinGreen Biotech Co., Ltd.

UNKNOWN

lead

Kawin Technology Share-holding Co., Ltd.

INDUSTRY